Concomitant inhibition of the thioredoxin system and nonhomologous DNA repair potently sensitizes Philadelphia‐positive lymphoid leukemia to tyrosine kinase inhibitors
HemaSphere · 2024-03 · 8 (3)
DOI: 10.1002/hem3.56 ↗Kurz gefasst
Fachartikel in der Zeitschrift HemaSphere, online erschienen am 14.03.2024. Verfasst von Lukasz Komorowski und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology Medical University of Warsaw Warsaw Poland. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Narodowe Centrum Nauki.
Abstract (Originalsprache)
Breakpoint cluster region‐Abelson ( BCR::ABL1 ) gene fusion is an essential oncogene in both chronic myeloid leukemia (CML) and Philadelphia‐positive (Ph + ) B‐cell acute lymphoblastic leukemia (B‐ALL). While tyrosine kinase inhibitors (TKIs) are effective in up to 95% of CML patients, 50% of Ph + B‐ALL cases do not respond to treatment or relapse. This calls for new therapeutic approaches for Ph + B‐ALL. Previous studies have shown that inhibitors of the thioredoxin (TXN) system exert antileukemic activity against B‐ALL cells, particularly in combination with other drugs. Here, we present that peroxiredoxin‐1 (PRDX1), one of the enzymes of the TXN system, is upregulated in Ph + lymphoid as compared to Ph + myeloid cells. PRDX1 knockout negatively affects the viability of Ph + B‐ALL cells and sensitizes them to TKIs. Analysis of global gene expression changes in imatinib‐treated, PRDX1‐deficient cells revealed that the nonhomologous end‐joining (NHEJ) DNA repair is a novel vulnerability of Ph + B‐ALL cells. Accordingly, PRDX1‐deficient Ph + B‐ALL cells were susceptible to NHEJ inhibitors. Finally, we demonstrated the potent efficacy of a novel combination of TKIs, TXN inhibitors, and NHEJ inhibitors against Ph + B‐ALL cell lines and primary cells, which can be further investigated as a potential therapeutic approach for the treatment of Ph + B‐ALL.
Autor:innen und Institutionen
- Department of Immunology Medical University of Warsaw Warsaw Poland.
- Postgraduate School of Molecular Medicine Medical University of Warsaw Warsaw Poland.
- Laboratory of Immunology, Mossakowski Medical Research Institute Polish Academy of Sciences Warsaw Poland.
- Department of Pediatrics, Oncology and Hematology Medical University of Lodz Lodz Poland.
- Polpharma Biologics SA Gdańsk Poland.
- Department of Psychology SWPS University of Social Sciences and Humanities Warsaw Poland.
ORCID-Profile: Lukasz Komorowski
Förderung
- Narodowe Centrum Nauki
Zitieren
APA
Komorowski, L., Dabkowska, A., Madzio, J., Pastorczak, A., Szczygiel, K., Janowska, M., Fidyt, K., Bielecki, M., Hunia, J., Bajor, M., Stoklosa, T., Winiarska, M., Patkowska, E., & Firczuk, M. (2024). Concomitant inhibition of the thioredoxin system and nonhomologous DNA repair potently sensitizes Philadelphia‐positive lymphoid leukemia to tyrosine kinase inhibitors. HemaSphere, 8(3). https://doi.org/10.1002/hem3.56
Vancouver
Komorowski L, Dabkowska A, Madzio J, Pastorczak A, Szczygiel K, Janowska M, et al. Concomitant inhibition of the thioredoxin system and nonhomologous DNA repair potently sensitizes Philadelphia‐positive lymphoid leukemia to tyrosine kinase inhibitors. HemaSphere. 2024;8(3). doi:10.1002/hem3.56
BibTeX
@article{Komorowski2024,
author = {Komorowski, Lukasz and Dabkowska, Agnieszka and Madzio, Joanna and Pastorczak, Agata and Szczygiel, Kacper and Janowska, Martyna and Fidyt, Klaudyna and Bielecki, Maksymilian and Hunia, Jaromir and Bajor, Malgorzata and Stoklosa, Tomasz and Winiarska, Magdalena and Patkowska, Elzbieta and Firczuk, Malgorzata},
title = {Concomitant inhibition of the thioredoxin system and nonhomologous DNA repair potently sensitizes Philadelphia‐positive lymphoid leukemia to tyrosine kinase inhibitors},
journal = {HemaSphere},
year = {2024},
volume = {8},
number = {3},
doi = {10.1002/hem3.56}
}
EUVIMED